CN104936592A - 一种注射用hpph冻干粉针制剂及其制备方法 - Google Patents

一种注射用hpph冻干粉针制剂及其制备方法 Download PDF

Info

Publication number
CN104936592A
CN104936592A CN201480005064.9A CN201480005064A CN104936592A CN 104936592 A CN104936592 A CN 104936592A CN 201480005064 A CN201480005064 A CN 201480005064A CN 104936592 A CN104936592 A CN 104936592A
Authority
CN
China
Prior art keywords
hpph
injection
freeze
cosolvent
solubilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201480005064.9A
Other languages
English (en)
Other versions
CN104936592B (zh
Inventor
冯春荣
张环伟
王剑桥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHEJIANG HAIZHENG PHARMACEUTICAL CO Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Priority to CN201480005064.9A priority Critical patent/CN104936592B/zh
Publication of CN104936592A publication Critical patent/CN104936592A/zh
Application granted granted Critical
Publication of CN104936592B publication Critical patent/CN104936592B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种注射用HPPH冻干粉针制剂及其制备方法。该冻干粉针制剂含有HPPH、助溶剂、增溶剂、赋形剂、pH调节剂。所述的HPPH冻干粉针制剂疏松，复溶性好，水分低，稳定性好。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201480005064.9A 2013-02-05 2014-01-21 一种注射用hpph冻干粉针制剂及其制备方法 Active CN104936592B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480005064.9A CN104936592B (zh) 2013-02-05 2014-01-21 一种注射用hpph冻干粉针制剂及其制备方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201310046627.6A CN103961323B (zh) 2013-02-05 2013-02-05 一种注射用hpph冻干粉针制剂及其制备方法
CN2013100466276 2013-02-05
CN201480005064.9A CN104936592B (zh) 2013-02-05 2014-01-21 一种注射用hpph冻干粉针制剂及其制备方法
PCT/CN2014/070974 WO2014121691A1 (zh) 2013-02-05 2014-01-21 一种注射用hpph冻干粉针制剂及其制备方法

Publications (2)

Publication Number Publication Date
CN104936592A true CN104936592A (zh) 2015-09-23
CN104936592B CN104936592B (zh) 2018-05-11

Family

ID=51231650

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310046627.6A Active CN103961323B (zh) 2013-02-05 2013-02-05 一种注射用hpph冻干粉针制剂及其制备方法
CN201480005064.9A Active CN104936592B (zh) 2013-02-05 2014-01-21 一种注射用hpph冻干粉针制剂及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310046627.6A Active CN103961323B (zh) 2013-02-05 2013-02-05 一种注射用hpph冻干粉针制剂及其制备方法

Country Status (8)

Country Link
US (1) US9717795B2 (zh)
EP (1) EP2954898B1 (zh)
JP (1) JP6235614B2 (zh)
KR (1) KR101804206B1 (zh)
CN (2) CN103961323B (zh)
CA (1) CA2900120C (zh)
HK (1) HK1211871A1 (zh)
WO (1) WO2014121691A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306326B (zh) * 2014-09-25 2016-10-05 江苏红豆杉药业有限公司 含有hpph的水性药物组合物和注射液
CN108586468B (zh) * 2018-01-10 2020-06-23 浙江海正药业股份有限公司 一种hpph的纯化方法
CN113577034A (zh) * 2021-08-30 2021-11-02 苏州素仕生物科技有限公司 一种兽用促黄体素释放激素a3冻干粉针剂及制备方法
KR20230126654A (ko) * 2022-02-23 2023-08-30 주식회사 엘지화학 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0331283A (ja) * 1989-06-14 1991-02-12 Quadra Logic Technol Inc 安定な凍結乾燥したポリヘマトポルフイリンエーテル／エステル組成物
WO2003028628A2 (en) * 2001-10-03 2003-04-10 Miravant Pharmaceuticals, Inc. Photosensitizing carbamate derivatives
CN101219137A (zh) * 2007-01-09 2008-07-16 健康研究有限公司 使用光动力疗法对食道高度发育异常的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166719B2 (en) * 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
WO2004067508A2 (en) * 2003-01-24 2004-08-12 The Research Foundation Of State University Of Newyork Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
US20100056983A1 (en) * 2007-09-27 2010-03-04 Health Research, Inc. Treatment of cancer using photodynamic therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0331283A (ja) * 1989-06-14 1991-02-12 Quadra Logic Technol Inc 安定な凍結乾燥したポリヘマトポルフイリンエーテル／エステル組成物
WO2003028628A2 (en) * 2001-10-03 2003-04-10 Miravant Pharmaceuticals, Inc. Photosensitizing carbamate derivatives
CN101219137A (zh) * 2007-01-09 2008-07-16 健康研究有限公司 使用光动力疗法对食道高度发育异常的治疗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENGPAN WU等: "Efficacy of 2‑(1‑hexyloxyethyl)‑2‑devinyl pyropheophorbide‑a in photodynamic therapy of human esophageal squamous cancer cells", 《ONCOLOGY LETTERS》 *

Also Published As

Publication number Publication date
KR20150113184A (ko) 2015-10-07
EP2954898A4 (en) 2016-08-03
WO2014121691A1 (zh) 2014-08-14
US9717795B2 (en) 2017-08-01
CN104936592B (zh) 2018-05-11
US20150366965A1 (en) 2015-12-24
EP2954898A1 (en) 2015-12-16
KR101804206B1 (ko) 2017-12-04
CN103961323A (zh) 2014-08-06
CA2900120C (en) 2018-07-03
CN103961323B (zh) 2017-10-17
JP6235614B2 (ja) 2017-11-22
HK1211871A1 (zh) 2016-06-03
JP2016506936A (ja) 2016-03-07
EP2954898B1 (en) 2019-04-24
CA2900120A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
CN102614118B (zh) 注射用盐酸表柔比星制剂的制备方法及制剂
CN104936592A (zh) 一种注射用hpph冻干粉针制剂及其制备方法
CN102481288B (zh) 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法
CN100438855C (zh) 重酒石酸长春瑞滨脂质体及其冻干粉针与制备方法
CN102133191A (zh) 一种转铁蛋白和白蛋白复合纳米粒及其制备方法和用途
CN105078904B (zh) 一种卡巴他赛脂微球白蛋白冻干粉针及其制备方法
CN107865824B (zh) 一种稳定的重组人血管内皮抑制素皮下注射组合物
CN102525954A (zh) 左旋棉酚及其醋酸盐的注射用冻干乳制剂
CN105435225A (zh) 注射用二氢卟吩e6单酯冻干制剂及其制备方法
CN102670579B (zh) 一种紫杉醇药物组合物及其制备方法
CN109044969B (zh) 一种紫杉醇注射液的制备方法
EP3679925A1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
CN104829653B (zh) 一种奥沙利铂水合物晶体及其冻干粉针剂
CN106176626B (zh) L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物
CN104490800B (zh) 一种福司氟康唑冻干粉组合物及其制备方法
CN108272755B (zh) 一种注射用盐酸吗替麦考酚酯冻干制剂及其制备方法
CN100450476C (zh) 注射用电解质补充药组合物
CN105106930A (zh) 一氧化氮供体型谷胱甘肽类化合物冻干粉针剂及应用
CN109925283B (zh) 一种替莫唑胺药物组合物及其制备方法
CN114010671A (zh) 一种用于治疗黑色素瘤的黑人参纳米乳、制备方法及应用
CN1376468A (zh) 注射用羟基喜树碱冻干粉针制剂及其制备方法
CN100560572C (zh) 甘氨双唑酸的碱性氨基酸盐及其制备和用途
CN104510708B (zh) 一种米铂冻干制剂及其制备方法
CN104306326B (zh) 含有hpph的水性药物组合物和注射液
CN117797135A (zh) 一种紫杉醇衍生物缓释剂的制备及用途

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20191113

Address after: 201600 building 3, No. 301, Minqiang Road, Songjiang District, Shanghai

Co-patentee after: Zhejiang Haizheng Pharmaceutical Co., Ltd.

Patentee after: Shanghai Angrui Pharmaceutical Technology Co., Ltd

Address before: Jiaojiang District of Taizhou City, Zhejiang province 318000 road outside No. 46

Patentee before: Zhejiang Haizheng Pharmaceutical Co., Ltd.